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PURPOSE. To study clinical and in vivo laser scanning confocal microscopy (LSCM) ocular
surface findings in stable, medically controlled primary open-angle glaucoma (MCPOAG)
patients.
METHODS. We recruited 100 consecutive patients with MCPOAG and 50 healthy controls.
Patients had to have been treated with the same medical regimen without variation for the 18
months before enrollment and were excluded if there was a history of dry eye prior to
glaucoma diagnosis. Each participant underwent ocular surface clinical and LSCM
examination.
RESULTS. In MCPOAG patients, subbasal nerve length and tortuosity and dendritic cell density
were increased compared to controls (P < 0.01), but there were no clinical abnormalities.
Patients treated with preserved drugs (n ¼ 80) had reduced tear film breakup time (P < 0.05,
ANOVA), and those preserved with benzalkonium chloride (n ¼ 72) had reduced Schirmer
test values (P < 0.001). Patients (n ¼ 50) treated with two or more drugs had increased
lissamine green conjunctival staining (P < 0.001, LSD post hoc test). Patients (n ¼ 29) treated
with three or more eye drops daily had decreased Schirmer test values. Laser scanning
confocal microscopy showed subbasal changes related to preservatives, type and number of
drugs, and number of eye drops.
CONCLUSIONS. In stable MCPOAG patients without dry eye history, the ocular surface changes
due to antiglaucoma medications are mostly subclinical. Active ingredients, preservatives,
number of concomitant drugs, and number of eye drops instilled per day are all elements that
can induce ocular surface changes. The clinical relevance of these changes remains to be
determined.
Keywords: confocal microscopy, ocular surface, glaucoma medications, corneal epithelium,
inflammation
Primary open-angle glaucoma is a progressive optic neurop-athy that is often associated with an increased intraocular
pressure (IOP) and that may cause progressive visual field loss
leading to blindness.1 A series of large, multicenter, randomized
controlled studies demonstrated that IOP-lowering therapy can
prevent glaucoma onset from ocular hypertension and prevent
further progression in patients with confirmed diagnosis of
glaucoma.1–3 According to the European Glaucoma Society
Guidelines,4 the first-line approach to control IOP is with
medical treatment. Because of the progressive nature of the
disease, chronic treatment is required, with many patients
needing to use more than one drug to achieve a target IOP.
A frequently reported side effect of long-term antiglaucoma
topical treatment, occurring in up to 59% of patients,5–8 is
ocular surface disease. This is a symptomatic condition in
which the homeostasis between the tear film and the
components of the ocular surface morphofunctional unit is
disturbed.9 The main symptoms are dryness, foreign body
sensation, tearing, burning, and redness. The main signs are
reduced tear stability and secretion, corneal and conjunctival
staining, and meibomian gland dysfunction.5–8 This condition
may affect the patient’s quality of life10,11 and might influence
compliance to therapy.12,13
Ocular surface disease related to antiglaucoma drugs may
result from either an allergic or a toxic mechanism.14,15 Allergic
responses are relatively rare and more often evident in the early
phase of therapy.15,16 Thus toxicity is likely to be the prevalent
cause of chronic ocular surface disease under these circum-
stances.14,15 This response might be attributed to preservatives
in topical medicines as well as to the active compounds, but the
relative role of these components is still being debated.15,17
Benzalkonium chloride (BAK) is the most commonly used
preservative in topical drugs, and a large body of recent
literature highlights its toxic effects on ocular tissues.14,18–22
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Moreover, an increase in the ocular surface symptoms and
signs is associated with the number of concomitant drugs and
the number of eye drops instilled per day,12,23 leading to the
hypothesis that the simpler the regimen, the more likely the
patient will tolerate and adhere to the therapeutic protocol.13
Drug-related ocular surface abnormalities may be identified,
even in asymptomatic patients, by an abnormal expression of
interleukins and inflammatory markers24–26 and by advanced
imaging techniques. In vivo laser scanning confocal microsco-
py (LSCM) is a technology that allows the study of living ocular
surface structures at a microstructural level in a quick and
nearly noninvasive way with a resolution comparable to that of
histologic methods.27 This technology showed promising
results in discerning different pathogenic processes in several
components of the ocular surface,27–32 in studying subclinical
changes,27,33 and in monitoring ocular surface changes and
responses to treatment.34–37
Current literature confocal data on glaucomatous patients38
are heterogeneous; they have been obtained in different
settings, sometimes retrospectively, and often provided by
studies with a very specific a priori hypothesis, as well as
important selection or confounding biases. Presumed anti-
glaucoma medication-related confocal findings include con-
junct iva l squamous metaplas ia , 3 9 desquamat ion ,
keratinization,38,40 dendritic cell activation,40 inflammation,15
goblet cell loss,15,41 increase of corneal dendritic cells and
activated keratocytes,38,42 decrease of corneal superficial
epithelial cell density,42 subbasal nerve decreased density and
increased tortuosity,42,43 reduced Meibomian gland glandular
density and area, increased reflectivity of the acinar secretion,
ductal orifice dilation, and signs of inflammation of the
glandular wall and interstice.44
We hypothesized that medically treated glaucoma patients,
compared to healthy subjects, have a subclinical neuro-
inflammatory process characterized by corneal nerve changes
and increased number of dendritic cells.
We designed the present prospective, explorative, compre-
hensive research to identify and characterize clinical and
confocal ocular surface changes in medically controlled
patients with primary open-angle glaucoma (MCPOAG) com-
pared to untreated, healthy control subjects and to investigate
abnormalities determined by the characteristics of the thera-
peutic regimen.
METHODS
We consecutively recruited a convenience sample of 100
Caucasian patients with MCPOAG and 50 untreated healthy
controls who were referred to our Glaucoma Service as
glaucoma suspects with family histories of glaucoma or optic
disc cupping. To be included in the study, the MCPOAG
patients had to have been treated with the same medical
regimen without variation for the 18 months before enroll-
ment. Participants were excluded from the study if they had a
history of ocular or systemic diseases or treatments (except
antiglaucoma medications for MCPOAG patients) within the
last 12 months with known effects on the ocular surface. Other
exclusion criteria were previous ocular surgery or trauma, end-
stage glaucoma, pregnancy, contact lens wear, and a history of
dry eye prior to glaucoma diagnosis.
Each participant completed an Ocular Surface Disease
Index (OSDI) questionnaire.45 The compliance of MCPOAG
patients to therapy was assessed by the Morisky-Green
medication adherence questionnaire, a validated self-reported
instrument with four questions.46 Each participant underwent
a comprehensive eye examination including an assessment of
the best corrected visual acuity, biomicroscopic examination of
the ocular surface, measurement of the tear film breakup time
(BUT), corneal fluorescein and conjunctival lissamine green
staining (Collaborative Longitudinal Evaluation of Keratoconus
[CLEK] scheme),47 Schirmer test without topical anesthesia,
corneal apex sensitivity assessment (Cochet-Bonnet esthesiom-
eter with nylon thread diameter of 0.08 mm; Luneau, Paris,
France), Schirmer test with anesthesia, IOP measurement
(Goldmann applanation tonometer), and meibomian gland
dropout (meiboscopy) and expressivity grading. Meiboscopy
of the lower eyelid was scored as follows: grade 0, no gland
dropout; grade 1, gland dropout in less than one-third of the
inferior tarsus; grade 2, gland dropout between one-third and
two-thirds; and grade 3, dropout in more than two-thirds of the
inferior tarsus.33,48 Assessment of obstruction in the meibo-
mian gland orifices was conducted by applying digital pressure
on the lower eyelid margin. The degree of ease in expressing
the meibum was evaluated semiquantitatively as follows: grade
0, clear meibum easily expressed; grade 1, cloudy meibum
expressed with mild pressure; grade 2, cloudy meibum
expressed with more than moderate pressure; grade 3,
meibum not be expressed even with hard pressure.33,48 All
of the procedures were performed in the order suggested by
the International Dry Eye WorkShop 2007 (DEWS).49
Following a previously published procedure, we also
performed in vivo LSCM examination of several ocular surface
components,32 including cornea, temporal bulbar conjunctiva,
inferior tarsal conjunctiva, meibomian glands, and eyelid
margin. We used the HRT II with Corneal Rostock Module
(Heidelberg Engineering, Dossenheim, Germany) with a
scanning wavelength of 670 nm. Before each examination, a
drop of oxybuprocaine chlorohydrate 0.4% and a drop of
ophthalmic gel (polyacrylic gel 0.2%) were separately instilled
in the lower conjunctival fornix of the patient. The objective
lens (363 immersion; Zeiss, Oberkochen, Germany) was
covered by a polymethacrylate sterile cap (Tomo-Cap; Heidel-
berg Engineering) and had a working distance of 0.0 to 2.0
mm. The examination area was 4003 400 lm.
Image Analysis
Confocal image analysis was performed, in a masked manner,
as previously described.32 For the cornea, we quantified
superficial and basal epithelial cell density; anterior, posterior,
and hyperreflective keratocyte density; subbasal dendritic cell
density; subbasal nerve length per frame50 and tortuosity51;
density of beading formations; and endothelial cell density. For
the bulbar and tarsal conjunctivas, we evaluated epithelial and
immune cell density.52–54 For the lower eyelid margin and
meibomian glands, we quantified the following variables:
epithelial cell density, meibomian gland density, acinar unit
diameter, acinar unit area, meibum reflectivity, and inhomoge-
neous appearance of the interstices and walls of the acinar
units.
Cell density was determined through the manual cell
counting procedure present in the software, taking into
consideration the whole area marked as available for the
count. Cells partially contained in the area were counted only
along the right and lower margins of the selected field. Results
are expressed in cells per square millimeter. The same
procedure was performed for acinar density. ImageJ software
(available in the public domain at http://imagej.nih.gov/ij/) was
used to manually calculate the length of nerves per frame,
diameters of the acinar units (along the longest axis), and unit
areas (automatically calculated after manual demarcation of the
boundary).
Finally, using a comparison with previously published
reference images, we evaluated nerve tortuosity,51 meibum
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secretion reflectivity, and inhomogeneous appearance of
interstices and walls of acinar units.33
Informed consent was obtained from all patients, and the
study was performed in accordance with the tenets of the
declaration of Helsinki.
Statistical Analysis
Data derived from the worse eye (defined as the eye with the
higher fluorescein staining score or the higher lissamine green
score, or the lower BUT, in that order) were used for statistical
analysis. All data are expressed as means 6 standard deviations
(SD).
We compared MCPOAG patients to controls using indepen-
dent samples t-test for parametric variables and Mann-Whitney
U test for nonparametric variables. For each parametric
variable in which we found no significant difference between
MCPOAG and controls, we calculated the minimum detectable
difference (MDD; a ¼ 0.05, b ¼ 0.80) for that variable.
Subsequently, we divided MCPOAG patients into subgroups
based on the preservatives, active ingredients, number of
antiglaucoma medications, and number of eye drops instilled
per day. We compared clinical and confocal data among
subgroups by analysis of variance (ANOVA) and by least
significant difference (LSD) post hoc tests for parametric
variables and by Kruskal-Wallis tests for nonparametric
variables. Statistical significance was set at P < 0.05. Statistical
analysis was performed with commercial software (SPSS for
Windows v.19.0; SPSS Sciences, Chicago, IL, USA).
RESULTS
There were no significant differences in the age and sex
distributions between the MCPOAG patients (72 women and
28 men; average age 57.3 6 7.5 years, range, 44–77 years) and
the control group (31 women and 19 men; average age 54.6 6
6.2 years, range, 41–75 years). All of the patients reported good
compliance to treatment with a Morisky-Green medication
adherence questionnaire score ‡ 16,46 and demonstrated
awareness of their therapeutic regimen. The treatment
regimens of the patients included different preservatives,
active ingredients, number of drugs, and number of instilled
drops per day (Table 1).
There were no significant clinical differences between
MCPOAG patients and control subjects (Table 2). Confocal
examination showed increased nerve length, nerve tortuosity,
and dendritic cell density at the corneal subbasal level in
MCPOAG patients (Fig. 1; Table 2).
The preservative-based subgroup analysis of MCPOAG
patients identified three groups: patients treated with BAK-
preserved drugs (n ¼ 72), patients treated with Polyquad-
preserved drugs (n¼8), and patients treated with unpreserved
drugs (n ¼ 20). For eyes treated with BAK- and Polyquad-
preserved drugs, the BUT was significantly lower than for eyes
treated with preservative-free drugs (Fig. 2A). Further, the
Schirmer test times for eyes treated with BAK-preserved drugs
was lower than for eyes treated with Polyquad-preserved and
preservative-free drugs (Fig. 2B). Confocal data revealed
increased subbasal nerve tortuosity in both preserved groups
compared to the unpreserved group (Fig. 2C).
The subgroup analysis of MCPOAG patients based on active
ingredients identified three groups: patients treated with beta-
blockers (n ¼ 36), patients treated with prostaglandin
analogues (n ¼ 14), and patients treated with combination
drops of beta-blockers and prostaglandin analogues (n ¼ 50).
Lissamine green conjunctival staining was increased in the
combination group compared to both of the other groups and
was the only clinical parameter showing a significant
difference among these groups (Fig. 3A). Laser scanning
confocal microscopy examination found significant differences
among the groups only at subbasal level of the corneal
epithelium. The total length/frame and tortuosity of nerves was
lowest in the beta-blocker group. This reached statistical
significance for total length/frame when compared with the
combination group (Fig. 3B) and for tortuosity when compared
with both of the other groups (Fig. 3C). Moreover, patients
treated with beta-blockers had lower dendritic cell density
compared to both the prostaglandin analogue and combination
groups (Fig. 3D). No significant differences were found among
the different types of combinations.
The subgroup analysis based on the number of different
types of drugs taken by each MCPOAG patient identified three
groups: patients taking one drug (n¼ 50), patients taking two
drugs (n ¼ 32), and patients taking three or more drugs (n ¼
18). Again, lissamine green conjunctival staining was the only
clinical parameter that was significantly lower among the
groups. It was lower in patients treated with one drug
compared to either of the other groups (Fig. 4A). Confocal
data at the subbasal level showed significantly lower total
length/frame and tortuosity of nerves (Fig. 4B, 4C) and lower
dendritic cell density (Fig. 4D) in patients treated with one
drug compared to either of the other groups.
The subgroup analysis of MCPOAG patients based on the
number of drops taken per day identified three groups:
patients treated with one drop/day (n ¼ 27), patients treated
with two drops/day (n¼44), and patients treated with three or
more drops/day (range, 3–5, n ¼ 29). The Schirmer test was
decreased in the group treated with the higher number of daily
drops (Fig. 5A), and the subbasal nerve tortuosity was lower in
the group treated with two drops/day (Fig. 5B). No other
variables showed significant differences in this subanalysis.
DISCUSSION
Antiglaucoma medical treatment is a chronic therapy and
exposes the ocular surface to the simultaneous actions of
different potential triggers such as active compounds, preser-
vatives, and repeated instillations. Despite a large body of
literature on the topic, the clinical relevance and the specific
ocular surface changes related to these triggers are not fully
understood. The present study, performed in a clinical setting,
excluded patients with a history of dry eye prior to glaucoma
TABLE 1. Subjects Included in the Study and Criteria Used for Group
Analyses
Number of
Subjects
Criteria for
Group Identification
MCPOAG 100 Treated/untreated
Untreated controls 50
BAK-preserved drugs 72 Type of preservative
Polyquad-preserved drugs 8
Preservative-free drugs 20
Beta-blocker drops 36 Type of active ingredient
Prostaglandin analogue drops 14
Combination drops 50
1 drug 50 Number of drugs
2 drugs 36
3 drugs 14
1 drop 27 Number of daily
instilled drops
2 drops 44
3 or more drops 29
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diagnosis and those with recent treatment changes. The
consecutive enrollment allowed analysis of a relatively large
sample of patients very similar to most of those seen in daily
clinical practice. To limit selection biases, we consecutively
recruited from the same clinical setting a control group of 50
untreated healthy subjects who were referred for family history
of glaucoma or optic disc cupping. To limit confounding
factors, due to the lack of a control group of untreated
glaucomatous subjects, we limited our confocal study to
parameters notoriously related to antiglaucoma medications
and did not consider conjunctival microcysts and other
features previously described in treated and also in untreated
glaucoma patients.55,56
Moreover, we included only previously validated confocal
parameters, and we adopted an approach, recently described
and applied to dry eye patients,32 that obtained simultaneous
optical samples of several components of the ocular surface
morphofunctional unit. This kind of comprehensive confocal
analysis is very complex and time-consuming, and therefore it
is not suitable for daily clinical use. Nevertheless, it can provide
important information to identify the type of ocular surface
changes related to different conditions.
In this exploratory research to screen subtle abnormalities
related to MCPOAG and to different treatment features, we
adopted an approach highlighting the differences between
groups, that is, selecting the worse eye per subject and using
the least significant difference as the ANOVA post hoc test.
Further, to reduce concerns regarding the power of the
analysis, the MMD was calculated for each t-test that was
statistically insignificant.
TABLE 2. MCPOAG Patients Versus Controls: Ocular Surface Clinical and Confocal Data
MCPOAG Patients Control Subjects P MDD
OSDI 11.91 6 12.72 12.76 6 15.26 n.s.* 6.92
BUT, s 6.02 6 2.80 6.56 6 3.46 n.s.* 1.39
Corneal fluorescein staining, CLEK 0.56 6 0.82 0.49 6 0.73 n.s.† n.d.
Conjunctival lissamine green staining, CLEK 0.24 6 0.44 0.30 6 0.47 n.s.† n.d.
Schirmer test without topical anesthesia, mm/5 min 10.77 6 3.64 12.08 6 4.21 n.s.* 1.94
Corneal apex sensitivity, cm 5.45 6 0.93 5.74 6 0.72 n.s.* 0.42
Schirmer test with anesthesia, mm/5 min 9.94 6 3.39 10.80 6 3.25 n.s.* 1.57
Meibomian gland dropout, grade 0–3 0.89 6 0.58 0.88 6 0.67 n.s.† n.d.
Meibomian gland expressibility, grade 0–3 1.27 6 0.89 1.56 6 0.92 n.s.† n.d.
Corneal superficial epithelial cell density, cells/mm2 1747.23 6 352.10 1694.88 6 303.25 n.s.* 161.6
Corneal basal epithelial cell density, cells/mm2 5040.86 6 422.28 5159.74 6 290.81 n.s.* 194.84
Corneal anterior keratocyte density, cells/mm2 797.81 6 102.43 824.30 6 95.39 n.s.* 47.09
Corneal posterior keratocyte density, cells/mm2 537.63 6 61.04 514.85 6 51.81 n.s.* 28.16
Corneal hyperreflective keratocyte density, cells/mm2 47.45 6 35.74 54.32 6 52.37 n.s.* 20.31
Corneal subbasal dendritic cell density, cells/mm2 86.84 6 44.60 41.01 6 38.46 <0.01* n.d.
Corneal subbasal nerve length, lm/frame 2814.74 6 929.59 2077.68 6 575.91 <0.01* n.d.
Corneal subbasal nerve tortuosity, 0–4 2.00 6 0.78 1.20 6 0.40 <0.01† n.d.
Corneal subbasal nerve beading, n/mm 167.59 6 39.69 158.54 6 42.25 n.s.* 19.39
Corneal endothelial cell density, cells/mm2 2675.50 6 409.60 2788.56 6 330.25 n.s.* 188.83
Bulbar conjuntival epithelial cell density, cells/mm2 1538.92 6 301.26 1651.42 6 265.48 n.s.* 143.13
Bulbar conjuntival immune cell density, cells/mm2 31.84 6 27.73 28.37 6 22.49 n.s.* 12.47
Tarsal conjuntival epithelial cell density, cells/mm2 2747.15 6 543.97 2899.17 6 364.25 n.s.* 251.16
Tarsal conjuntival immune cell density, cells/mm2 152.23 6 112.78 187.58 6 104.52 n.s.* 52.17
Eyelid margin epithelial cell density, cells/mm2 1924.54 6 476.74 1910.64 6 463.23 n.s.* 219.77
MG acinar density, n/mm2 103.64 6 84.11 106.47 6 61.33 n.s.* 38.78
MG acinar diameter, lm 77.36 6 21.30 74.48 6 19.91 n.s.* 9.70
MG acinar area, lm2 3126.56 6 1314.18 3225.52 6 1375.82 n.s.* 634.83
MG secretion reflectivity, grade 1–4 1.93 6 0.92 2.12 6 0.97 n.s.† n.d.
Inhomogeneous appearance of MG walls, grade 1–4 2.02 6 0.80 1.96 6 0.84 n.s.† n.d.
Inhomogenous appearance of MG interstices, grade 1–4 1.62 6 0.63 1.56 6 0.58 n.s.† n.d.
MG, meibomian glands; n.s., not significant; n.d., not determined.
* Independent samples t-test.
† Mann-Whitney U test.
FIGURE 1. LSCM significant differences: MCPOAG patients versus control group. Data presented as mean 6 standard deviation. (A) Subbasal nerve
total length/frame (lm): MCPOAG: 2814.746 929.59; control group: 2077.686 575.91; P < 0.01 from t-test. (B) Subbasal nerve tortuosity (grading
1–4): MCPOAG: 2.0 6 0.8; control group: 1.2 6 0.4; P < 0.01 from Mann-Whitney U test. (C) Subbasal dendritic cell density (cell/mm2): MCPOAG:
86.84 6 44.60; control group 41.01 6 38.46; P < 0.01 from t-test.
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Initially, we compared MCPOAG patients to healthy controls
and found significant results at the level of the corneal subbasal
nerve plexus with increased total nerve length and tortuosity
and with increased dendritic cell density. The increased length
of nerves per frame is probably due to the increased tortuosity
in absence of decreased nerve density. We decided to adopt
this parameter to quantitatively assess the subbasal plexus
because in previous research it showed the best interobserver
and intervisit agreement compared to analysis of nerve and
branch density.57 Comparison of these results with the
literature is not easily done because of the heterogeneity of
methodologies adopted in previously published research.
However, microscopic changes in the subbasal nerve plexus
in glaucoma patients due to medical treatment have been
described.38,42,58 The coexistence of increased subbasal nerve
tortuosity and increased dendritic cell density suggests the
presence of neuroinflammatory processes in which the early
changes in fiber morphology can occur even without evident
nerve loss or clinically appreciable decrease of sensitivity. This
kind of inflammatory neuropathy, never clearly described in
glaucoma patients, has been recently reported, or at least
hypothesized based on imaging, in dry eye, diabetes, and small-
fiber neuropathies.32,59,60
We investigated the differences among the antiglaucoma
treatment regimens in a posteriori subgroup analyses.
We compared MCPOAG patients treated with BAK-pre-
served, Polyquad-preserved, and unpreserved drugs. Concerns
regarding toxic effects of preservatives, supported by a rapidly
growing body of literature, appear to have persuaded
companies to develop and intensively market unpreserved
antiglaucoma medications. These unpreserved drops may
avoid the adverse effects of preservatives on the ocular surface;
but they are more expensive, and the single-dose vials may be
more difficult for an older patient to use. In addition, data from
clinical trials, as discussed by Baudouin,15 provide reassurance
that long-term use of preserved antiglaucoma treatments is
well tolerated and not harmful. The role of BAK has been
recently investigated by numerous studies designed to evaluate
the toxic effect of the preservative on the ocular surface and
the risk–benefit ratio in glaucoma therapy.14,15,18–26 Many in
vitro and in vivo studies have established that BAK causes
damage, characterized by inflammation and apoptosis, to
corneal and conjunctival cells.24–26 However, the clinical
relevance of these findings is controversial because the toxic
dose used is often greater than that used in clinical practice.
Berdy et al.23 reported that there are no significant adverse
effects associated with the use of eye drops containing BAK up
to four to six times daily in patients with mild dry eye disease.
We found significant preservative-related decreases in BUT
and the Schirmer test without topical anesthesia and higher
subbasal nerve tortuosity. Specifically, we found that the
Schirmer test values in BAK-containing drugs were significantly
lower than those of both Polyquad-preserved and unpreserved
drugs. Further, nerve tortuosity was higher in eyes treated with
both BAK- and Polyquad-preserved drugs compared to the
unpreserved drugs. This is in contrast to an in vivo confocal
study by Martone and colleagues42 that described no signifi-
cant subbasal differences between BAK-preserved and BAK-
FIGURE 2. MCPOAG patients treated with BAK-preserved drugs, Polyquad-preserved drugs, and preservative-free drugs: clinical and confocal
significant differences. (A) Tear film breakup time (seconds): BAK-preserved drugs: 5.62 6 2.79; Polyquad-preserved drugs: 5.62 6 3.50;
preservative-free drugs: 7.55 6 2.54; P < 0.05 from ANOVA; *BAK-preserved drugs versus preservative-free drugs P < 0.001, LSD post hoc test. (B)
Schirmer test without topical anesthesia (mm/5 min): BAK-preserved drugs: 8.85 6 3.54; Polyquad-preserved drugs: 13.626 2.50; preservative-free
drugs: 11.30 6 4.52; P < 0.001 from ANOVA; *BAK-preserved drugs versus preservative-free drugs P < 0.001, LSD post hoc test; **BAK-preserved
drugs versus Polyquad-preserved drugs P < 0.05, LSD post hoc test. (C) Subbasal nerve tortuosity (grading 1–4): BAK-preserved drugs: 2.06 6 0.81;
Polyquad-preserved drugs: 2.37 6 0.52; preservative-free drugs: 1.65 6 0.67; P < 0.05 from Kruskal-Wallis test; *BAK-preserved drugs versus
preservative-free drugs P < 0.05, Mann-Whitney U test; **Polyquad-preserved drugs versus preservative-free drugs P < 0.05, Mann-Whitney U test.
FIGURE 3. MCPOAG patients treated with beta-blockers, prostaglandin analogues, and combinations of the two: clinical and confocal significant
differences. (A) Lissamine green conjunctival staining. Beta-blocker drugs: 0.17 6 0.36; prostaglandin analogue drugs: 0.14 6 0.36; combination of
beta-blocker and prostaglandin analogue drugs: 0.44 6 0.53; P < 0.05 from ANOVA; *beta-blockers drugs versus combination of drugs P < 0.001,
LSD post hoc test. (B) Subbasal nerve total length/frame (lm). Beta-blocker drugs: 2411.42 6 757.35; prostaglandin analogue drugs: 2793.43 6
867.13; combination of drugs: 3111.106 963.04; P < 0.001 from ANOVA; *beta-blocker drugs versus combination of drugs P < 0.001, LSD post hoc
test. (C) Subbasal nerve tortuosity (grading 1–4). Beta-blocker drugs: 1.446 0.56; prostaglandin analogue drugs: 1.866 0.66; combination of drugs:
2.44 6 0.67; P < 0.001 from Kruskal-Wallis test; *beta-blocker drugs versus combination of drugs P < 0.001, Mann-Whitney U test; **beta-blocker
drugs versus prostaglandin analogue drugs P < 0.001, Mann-Whitney U test. (D) Subbasal dendritic cell density (cell/mm2): beta-blocker drugs:
55.05 6 36.73; prostaglandin analogue drugs 97.79 6 40.80; combinations: 106.67 6 37.88; P < 0.001 from ANOVA; *beta-blocker drugs versus
combinations P < 0.001, LSD post hoc test; **beta-blocker drugs versus prostaglandin analogue drugs P < 0.05, LSD post hoc test.
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free drugs. In addition, a recent study evaluated the effects of
prostaglandin analogues and BAK in different concentrations of
the active compound and demonstrated that the active
compound has a greater effect on the tolerability of the
antiglaucoma therapy than the preservative.61 It is our opinion
that, in addition to research designed to demonstrate the
toxicity of preservatives, there is a need for further research
designed to assess the clinical impact of preservatives on the
ocular surface health in glaucoma patients with and without
dry eye.
Previous studies have demonstrated the detrimental clinical
and microscopic effects of multidrug therapy compared with a
single drug. These include a higher mean OSDI score,62
subconjunctival inflammatory reaction, ocular surface squa-
mous metaplasia,63 and meibomian gland confocal alter-
ations.44 We identified MCPOAG subgroups based on the
type of antiglaucoma drug they were using, that is, beta-
blockers, prostaglandin analogues, or a combination of the
two, and according to the number of antiglaucoma medica-
tions they were taking, that is, one, two, or three or more
drugs. Lissamine green staining of the conjuctiva was higher in
patients treated with combinations and in patients taking two
or more different drugs. Subbasal nerve length was lower in
patients treated with beta-blocker drugs and in patients taking
only one drug. Subbasal nerve tortuosity was lower in patients
taking beta-blocker drugs and in patients taking only one drug.
Subbasal dendritic cell density was lower in patients taking
beta-blocker drugs and in those taking only one drug. In
general, the post hoc tests showed that the differences were
greater when effects of a single drug were compared to the
effects of two or more drugs.
The subgroup analysis based on the number of eye drops
instilled per day showed a significant and interesting reduction
of Schirmer test values in patients treated with three or more
drops per day. Our data suggest that in addition to the ocular
surface effects of the topical antiglaucoma medications
themselves and the preservatives used, effects are also
associated with the number of different types of drugs and
even the number of drops instilled into the eyes.
Limitations of the present study include the lack of a group
of untreated glaucomatous subjects, its exploratory design
based on a rather general hypothesis, and the limited number
of patients. Moreover, the study design and the sample size
allowed us to perform interesting subgroup analyses but not to
provide final information on the relative impact of each
therapeutic regimen on the ocular surface.
In conclusion, in stable, medically treated glaucoma
patients with good compliance to therapy and no dry eye
history, the ocular surface changes due to antiglaucoma
medications are mostly subclinical. Active ingredients, preser-
vatives, the number of concomitant drugs, and the number of
eye drops instilled per day are all elements that are able to
induce different ocular surface changes, potentially with
synergistic effects. The clinical relevance of these changes is
not clear, but the results of this study suggest that the ocular
surface concerns regarding antiglaucoma medication may have
been overestimated. Data provided by this explorative research
may be important to planning future well-designed studies,
based on specific hypotheses and confirmatory data analysis.
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